That's not an overzealous presumption. ACXP is emerging as the odds-on favorite to get an effective C. difficile (CDI) drug to market. In fact, its Phase 2b ibezapolstat candidate demonstrates things others can't. And that's attracting a lot of attention, not only from investors following this under-the-radar company but likely from big pharma companies who may want a piece of ACXP's expected success in commercializing a drug to treat patients in a more than
Here's the exciting part of the ACXP investment proposition: investors taking advantage of current prices may be early to the game despite the near 30% jump. That's because government and sponsored grant funding could provide a cash war chest for ACXP to take its ibezapolstat to the finish line without partnership interest. If so, several companies that missed primary endpoints in their C. difficile studies could be left on the outside looking in. And investors know that big pharma rarely likes to give up billion-dollar market opportunities. Nor do they want to admit defeat.
Therefore, with a market cap of just
The better news...there are reasons for each to act sooner than later.
An Unpolished Biotech Gem
The opportunity for grant money has been noted. But the more significant attraction to ACXP from an investor's perspective is that the company may be the last drug company standing in the race to get an effective C. difficile drug treatment to market. Remember that ACXP isn't in the race to treat symptoms; it could have a cure. That difference is an advantage, a critical one, that other companies have failed to achieve. And there have been plenty of failures.
Over the past decade, disappointing clinical results in treating CDI have led several big pharma companies to drop off the clinical radar. Those still pursuing its CDI treatment candidate may be doing so with hopes of potentially treating, at best, niche indications of the infection. The latest disappointing data came from
Another pharmaceutical company,
It's appropriate to note that FNCH's Phase 2 data was impressive compared to
Better than ACXP? Not likely.
ACXP's Ibezapolstat Shows 100% Success
Acurx's ibezapolstat candidate published Phase 2a data showing it to be significantly better. Compared to Finch's candidate, which focuses on the microbiome as a single dimension and has only demonstrated a reduction in recurrent infection, the most significant advantage and point of superiority of ibezapolstat are that it's a dual impact drug that addresses the direct infection and, to date, avoids recurrent infection altogether. Better still, it restores the microbiome, a critical consideration.
The comparison to Finch's drug is appropriate because they may be the furthest along from a potential competitive perspective. Thus, the differences between the two candidates are timely. They also endorse a persuasive and data-justified argument that ACXP's candidate is seemingly better than Finch's one-dimension drug in cases of multiple recurrent infections. If that's the case, which current data suggests, ACXP's candidate could be the most ideally positioned treatment candidate to earn preferred first-line treatment designation.
Other than Finchs', no other candidate looks close to emerging as a serious competitive threat to ACXP's ibezapolstat's targeted front-line position. That's why others may need to pay to play; if they don't, they may find competing exceptionally hard.
So, who may want to partner with ACXP? Well, many might want to, but
Pfizer Would Be An Excellent Partner
Actually, blogs are already speculating that
And don't think PFE is blinded by unwarranted optimism about its CLOVER trial data. They are well aware its candidate failed to meet endpoints. It's also fair to suggest that they realize that if its candidate gets approved, it would likely be relegated to treating fringe and niche CDI treatment indications.
Therefore, while no investor should put it past PFE to spend up to hundreds of millions of dollars more to advance and commercialize an unpromising drug, more savvy ones are considering PFE's best course of action may be to partner and potentially capture a significant portion of the entire billion-dollar market opportunity with a drug showing the unique ability to cure the disease.
From ACXP's perspective, they could be in a win-win scenario. Yes, grant funding can eliminate many obstacles. But partnerships can too. And while having partners can dilute earnings after marketing approval, they add immediate value, potentially eliminate all ongoing trial costs, and add a level of experience in getting drugs approved. For ACXP investors, the trade-off would probably be well worth the interest given. However, it may not be as much as many think.
With best-in-class data in hand, ACXP could bargain from a position of strength. Remember, its data supports the potential for ibezapolstat to become the front-line therapy to treat over 500,000 patients who get CDI yearly. Of those 500,000, more than 20,000 patients per year die. So, while using the term infection, don't underestimate its potential 4% outcome. CDI can be fatal. For ACXP, it can mean a significant appreciation for what it has, and it's stock.
ACXP Puts A Cure For CDI In Sight
Okay, so why might ACXP's phone ring from those wanting to partner? Foremost, ACXP's Phase2a data showed 100% cure after 10 days of treatment, and 100% sustained cure after a 30-day follow-up. Thus, the totality of data, even noting Finch's one-dimensional eight-week sustained cure, shows ACXP's Phase 2a data to date constitutes the best clinical data seen in the CDI space.
It also demonstrated restoration of the patient's microbiome during treatment, which is highly unusual for an antibiotic. Considering that, it's reasonable to consider ibezapolstat as a potential "dual impact" therapy because it restores the microbiome while tending to the acute infection. That's not all attracting attention.
Its Ph2a trial was so impressive that it led the
The FDA may as well. They have already granted ACXP a Qualified Infectious Disease Product (QIDP) and a fast-track designation for its ibezapolstat treatment candidate. Perhaps it's fair to infer that they would be welcome to approve a drug that does exceedingly better than the current standard of care, Vancomycin, which has a recurrent infection rate of up to 40% with little evidence showing its value as an effective long-term treatment.
A Validated CDI Treatment Market
Once approved, ibezapolstat would likely meet overwhelming demand. A 2017 update of the Clinical Practice Guidelines for C. difficile infection by the
Acurx looks best positioned to meet the challenge. Data published from ACXP's Phase 2a trial in Clinical Infectious Diseases, one of the most respected journals in the medical community, indicates that ibezapolstat could be deserving of the front-line treatment crown. According to the article, ibezapolstat showed ideal traits as an oral antibiotics candidate, demonstrating a highly potent response against C. difficile, good tolerability, and limited gastrointestinal absorption. That resulted in very high fecal concentrations, which may reach three orders of magnitude above the MIC for C. difficile.
The article further noted that in addition to the ibezapolstat treatment being highly effective at killing C. difficile, it appears to do so while maintaining the populations of helpful bacteria in the gut microbiome. These signs indicate that the treatment may do more than cure CDI in the short term; it can significantly reduce the likelihood of recurrent infection.
Suitors May Call Sooner Than Later
What's it all mean? Put simply, there are reasons justifying ACXP's recent stock price surge. Still, at
Remember, ACXP is an under-the-radar, thinly traded stock. So, its sharp move higher is indeed worthy of attention. And not just by investors looking for an undervalued investment opportunity but by potential partners that may need to make their interest known to save potentially tens of millions in its cost to partner.
Know this too. Big pharma certainly does. Valuations of a Phase 3 drug company compared to a Phase 2 can amount to hundreds of millions in difference. Thus, under-estimating the speed at which ACXP can make that leap could be exponentially costly to potential suitors. More than likely, savvy ones aren't.
Hence, while ACXP stock is indeed in play, expect the game to get more intense, market-cap valuations to rise, and interest in ACXP to swell as its hoped-for first-line treatment candidate gets closer to commercialization. After all, having something others want can be a significant value driver. But more so in the pharmaceutical sector, where an asset worth potentially billions in new revenues can be transformative financially to the company owning it. For ACXP, that's the proposition they may offer.
And best of all, the ground floor opportunity, at least from an investor's perspective, is still there for the taking.
Disclaimers:
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Media Contact
Company
Contact Person:
Email: info@hawkpointmedia.com
Phone: 3057806988
City:
State:
Country:
Website: https://www.acurxpharma.com
.
(C) 2022 M2 COMMUNICATIONS, source